34680127|t|Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder.
34680127|a|Background: The efficacy of naltrexone in the treatment of alcohol use disorder (AUD) has been associated with a set of variables not directly related with the expression of opioid receptors. All the variables have been found to be highly associated with AUD itself or more severe clinical levels of AUD. Objectives: Given the high association between alcohol metabolizing enzymes (AME) and the outcome of AUD, the present study aims to investigate the role of AME genotype variants in the treatment of AUD with naltrexone. Methods: We carried out a 12-week longitudinal clinical trial based on the treatment of AUD patients with naltrexone (N = 101), stratified by different alcohol metabolization genotypes. Genotyping was performed after the inclusion of the patients in the study, based on the individual presence of single nucleotide polymorphisms (SNPs) in the ADH (alcohol dehydrogenase)1B (ADH1B*2 and ADH1B*3), ADH1C (ADHC*1) and ALDH (aldehyde dehydrogenase) 2 (ALDH2*2) genes. The outcome of alcohol use has been monitored employing the timeline follow-back during the treatment. Results: The ADH1C*1 (Ile350Val, rs698) and ALDH2*2 (Glu504Lys, rs671) polymorphisms were associated with a better response to naltrexone treatment, whereas the ADH1B*3 (Arg370Cys, rs2066702) allelic variant showed a negative outcome. Conclusions: The present study explores a genomic setting for the treatment of AUD with naltrexone. According to our findings, the association between ADH1C*1 and ALDH2*2 variants and better outcomes suggests a successful treatment, whereas the ADH1B*3 mutated allele might lead to an unsuccessful treatment. Further studies should be performed to investigate the relationship between alcohol metabolizing genotypes, the family history of alcohol use disorders and the effect of naltrexone on the outcomes. Genotyping may be a valuable tool for precision-medicine and individualized approach, especially in the context of alcohol use disorders. The small number of subjects was the main limitation of the present study.
34680127	22	29	Alcohol	Chemical	MESH:D000438
34680127	84	94	Naltrexone	Chemical	MESH:D009271
34680127	99	119	Alcohol Use Disorder	Disease	MESH:D000437
34680127	149	159	naltrexone	Chemical	MESH:D009271
34680127	180	200	alcohol use disorder	Disease	MESH:D000437
34680127	202	205	AUD	Disease	MESH:D000437
34680127	376	379	AUD	Disease	MESH:D000437
34680127	421	424	AUD	Disease	MESH:D000437
34680127	473	480	alcohol	Chemical	MESH:D000438
34680127	527	530	AUD	Disease	MESH:D000437
34680127	624	627	AUD	Disease	MESH:D000437
34680127	633	643	naltrexone	Chemical	MESH:D009271
34680127	733	736	AUD	Disease	MESH:D000437
34680127	737	745	patients	Species	9606
34680127	751	761	naltrexone	Chemical	MESH:D009271
34680127	797	804	alcohol	Chemical	MESH:D000438
34680127	883	891	patients	Species	9606
34680127	988	1017	ADH (alcohol dehydrogenase)1B	Gene	125
34680127	1041	1046	ADH1C	Gene	126
34680127	1060	1091	ALDH (aldehyde dehydrogenase) 2	Gene	217
34680127	1093	1098	ALDH2	Gene	217
34680127	1124	1131	alcohol	Chemical	MESH:D000438
34680127	1234	1243	Ile350Val	ProteinMutation	tmVar:p|SUB|I|350|V;HGVS:p.I350V;VariantGroup:0;CorrespondingGene:126;RS#:698;CorrespondingSpecies:9606;CA#:127870
34680127	1245	1250	rs698	SNP	tmVar:rs698;VariantGroup:0;CorrespondingGene:126;RS#:698;CorrespondingSpecies:9606
34680127	1256	1261	ALDH2	Gene	217
34680127	1265	1274	Glu504Lys	ProteinMutation	tmVar:p|SUB|E|504|K;HGVS:p.E504K;VariantGroup:2;CorrespondingGene:217;RS#:671;CorrespondingSpecies:9606;CA#:128085
34680127	1276	1281	rs671	SNP	tmVar:rs671;VariantGroup:2;CorrespondingGene:217;RS#:671;CorrespondingSpecies:9606
34680127	1339	1349	naltrexone	Chemical	MESH:D009271
34680127	1382	1391	Arg370Cys	ProteinMutation	tmVar:p|SUB|R|370|C;HGVS:p.R370C;VariantGroup:1;CorrespondingGene:125;RS#:2066702;CorrespondingSpecies:9606;CA#:127875
34680127	1393	1402	rs2066702	SNP	tmVar:rs2066702;VariantGroup:1;CorrespondingGene:125;RS#:2066702;CorrespondingSpecies:9606
34680127	1526	1529	AUD	Disease	MESH:D000437
34680127	1535	1545	naltrexone	Chemical	MESH:D009271
34680127	1610	1615	ALDH2	Gene	217
34680127	1832	1839	alcohol	Chemical	MESH:D000438
34680127	1886	1907	alcohol use disorders	Disease	MESH:D000437
34680127	1926	1936	naltrexone	Chemical	MESH:D009271
34680127	2069	2090	alcohol use disorders	Disease	MESH:D000437
34680127	Association	MESH:D000438	MESH:D009271
34680127	Negative_Correlation	MESH:D009271	RS#:698;HGVS:p.I350V;CorrespondingGene:126
34680127	Negative_Correlation	MESH:D009271	MESH:D000437
34680127	Negative_Correlation	MESH:D009271	RS#:2066702;HGVS:p.R370C;CorrespondingGene:125
34680127	Negative_Correlation	MESH:D009271	RS#:698;HGVS:p.I350V;CorrespondingGene:126
34680127	Negative_Correlation	MESH:D009271	RS#:671;CorrespondingGene:217
34680127	Positive_Correlation	MESH:D009271	RS#:671;HGVS:p.E504K;CorrespondingGene:217
34680127	Association	MESH:D000438	MESH:D000437
34680127	Negative_Correlation	MESH:D009271	RS#:2066702;HGVS:p.R370C;CorrespondingGene:125
34680127	Negative_Correlation	MESH:D009271	RS#:671;HGVS:p.E504K;CorrespondingGene:217
34680127	Negative_Correlation	MESH:D009271	RS#:2066702;CorrespondingGene:125
34680127	Negative_Correlation	MESH:D009271	RS#:698;CorrespondingGene:126
34680127	Association	MESH:D000438	217
34680127	Association	MESH:D009271	217

